Summary

The material contained in this presentation is intended to be general background information about Visioneering Technologies, Inc. (“VTI”, or “Visioneering”) and its activities.

The information is provided in a summary form, does not purport to be complete and may include information derived from publicly available sources that have not been independently verified. Accordingly, this presentation should not be relied upon as advice for investors or potential investors. It should be read in conjunction with VTI’s periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (“ASX”), which are available at www.asx.com.au.

No representation or warranty is made as to the accuracy, completeness or reliability of the information.

No financial product advice

This presentation is for information purposes only and does not take into account the investment objectives, financial position or needs of any particular investor. Investors or potential investors should seek independent professional advice in respect of their specific investment objectives, financial situation and particular needs before making any investment decision. VTI is not licensed to provide financial product advice in respect of its securities or any other financial products.

Risks

An investment in VTI is subject to known and unknown risks, some of which are beyond the control of VTI and its directors. VTI does not guarantee any particular rate of return in relation to VTI securities or the performance of VTI.

Forward-looking statements

Certain statements in this presentation may constitute forward-looking statements or statements about future matters that are based on management’s current expectations and beliefs (being statements about matters that are not historical facts), including but not limited to, statements related to VTI’s financial performance, business strategy and goals, plans and prospects, potential benefits of VTI’s products and technology, product development, timing of international regulatory approvals, market size, commercial success, and future financial performance. VTI uses words such as ‘will’, ‘may’, ‘expect’, ‘intend’, ‘seek’, ‘would’, ‘should’, ‘could’, ‘continue’, ‘plan’, ‘estimate’, ‘anticipate’, ‘believe’, ‘probability’, ‘risk’, ‘aim’, or other similar words to identify forward-looking statements.

These forward-looking statements are subject to risks and uncertainties that are difficult to predict and are based on assumptions as to future events that may not prove accurate.

Given the current uncertainties regarding the on-going impact of the COVID-19 on the trading conditions impacting VTI, the financial markets and the health services world-wide, there can be no assurance that future developments will be in accordance with VTI’s expectations or that the effect of future developments on VTI will be those anticipated. Actual results may differ materially from what is expressed in this presentation and investors are cautioned not to place undue reliance on the current trading outlook.

Past performance

Past performance, including the pro forma historical information in this presentation is given for illustrative purposes only and should not be relied on (and is not) an indication of future performance including future security price movements. Historical information in this presentation relating to VTI is information that has been released to the market. For further information, please see past announcements released to the ASX. Nothing contained in this presentation nor any information made available to investors or potential investors is, or shall be relied upon as, a promise, representation, warranty or guarantee, whether as to the past, present or future.

Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast.

CHESS Depositary Interests

VTI’s CHESS Depositary Interests (CDIs) are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933, as amended, and in accordance with the procedures established pursuant to the provisions of a no-action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no-action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this presentation.

No offer

This presentation is for information purposes only and is not and should not be considered an offer or an invitation to acquire securities or any other financial products in any jurisdiction in which, or to any person to whom, it would be unlawful to make such an offer or invitation.

Each recipient of this presentation should make its own enquiries and investigations regarding all information included in this presentation including the assumptions, uncertainties and contingencies which may affect VTI’s future operations and the values and the impact that future outcomes may have on VTI.

The information in this presentation is subject to change and unless required by law, VTI is under no obligation to update this presentation (including any forward-looking statements) or its contents for any matter arising or coming to VTI’s notice after the date of this presentation.

None of VTI, its officers, directors, employees and agents, nor any other person makes any representation or warranty, express or implied, as to, or endorsement of, VTI, the accuracy or completeness of any information, statements or representations contained in this presentation and none of them accepts responsibility or liability for any errors or omissions in this presentation whatsoever.

This document may not be reproduced or published, in whole or in part, for any purpose without the prior written consent of VTI. The distribution of this presentation outside of Australia may be restricted by law and any such restrictions should be observed.

This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in Australia, the United States or any other jurisdiction.
## Executive Summary

### Company and technology overview
- **Visioneering Technologies Inc** is a US-based ASX-listed medical device company that has developed, patented, and commenced selling a contact lens called NaturalVue Multi Focal (NaturalVue MF).
- NaturalVue MF is a soft contact lens that has been clinically shown to slow or halt the progression of myopia (short-sightedness) in children, and to correct presbyopia (age-related loss of near vision) in over-45 adults.
- The Company also markets other lenses for the simple correction of near- and far-sightedness.

### Investment Highlights
- **Strong start to FY21** – At midpoint of 1QFY21, company has recorded US$847K Shipments to US ECPs and approx US$800K net revenue.
- **Revenue growth despite COVID** – forecasting US$7m FY21 (~40% YOY growth).
- **Large market opportunity** – launched in markets with over $5bn+ addressable markets; further approvals expand opportunity to $10bn+.
- **Strategic partnership validates market and technology**
- **Multiple approvals in major geographies** – US, Europe, Canada, Australia, Hong Kong, Singapore.
- **Geographic expansion and new products in 2021 and 2022** – further rollout in Europe, Canada, and Asia, and two new product launches in 2021.
- **Sticky customer base with high repeat orders** – repeat customer rate greater than 90%.
- **Expanding gross margin** - 2020 gross margin 43.6%, increased from 34.4% in 2019, 4Q2020 gross margin was 46%.

### Significant Catalysts in 2021-2022
- Initiation of myopia control randomised clinical trial approximately 2Q2021 with yearly data readouts.
- Launch of next gen NaturalVue MF contact lens in approx. 3Q2021; Launch of NaturalVue MF Toric contact lens in approx. 4Q2021.
- Publication of peer reviewed clinical data on paediatric myopia control approximately 4Q2021.
- Continued organic growth in the US and Canada.
- Expanded rollout in Europe by strategic partners Menicon and Positive Impact, and by partner Oculus in Singapore and Hong Kong.

### Offer Details
- Raising up to A$23m, funding the company through to, or close to, break-even cash flow including new product launches, a clinical trial to obtain approval in the $10b China market, and a clinical trial to add to data that facilitates further market acceptance and strategic interest.
- Offering comprises a Placement of up to A$22m and a Share Purchase Plan to raise A$1m at A$0.017.
- Offer includes 1 free listed option for every 2 CDIs subscribed for under the Offer with a strike price of $0.03 and 3 year term to expiry.
I. Introduction to Visioneering
Experienced Leadership Team

Dr. Stephen Snowdy  
CEO and Executive Director

- Joined VTI as Chairman in May 2009 and has been Chief Executive Officer since June 2013
- 17 years of experience in life science venture investing and executive management
- Doctorate in Neurobiology and Master of Business Administration (Finance) from University of North Carolina. Bachelor of Science (Major in Chemistry) from University of Florida

Tony Sommer, Jr.  
Senior VP Sales & Marketing

- 20 years experience in sales and marketing management
- Previously Head of Sales for Bausch & Lomb’s US Vision Care division
- Bachelor of Science from the United States Air Force Academy and Master of Business Administration from Oklahoma City University

Brian Lane  
CFO

- CFO with extensive track record of strong financial results.
- CFO of a private equity-backed company and CAO of multiple public companies
- Career foundation built on 11 years with EY
- Bachelor of Business Administration, Accounting from University of Georgia
Highly Credentialed Board of Directors

Dr. David J. Mazzo
Chairman and Non-executive Director
- 40 years of experience in the life sciences industry
- Currently President, CEO and Executive Director of Caladrius Biosciences (NASDAQ:CLBS) and Board member of 2 NASDAQ-listed companies
- Previously served as CEO of several public companies, including leading Regado through its IPO

Christi Van Heek
Non-executive Director
- 25 years of experience in the life sciences industry
- Previously served as Vice President of Global Marketing for Genzyme, amongst other roles (acquired by Sanofi S.A. for >US$20bn)
- Board member of a NASDAQ-listed biotechnology company and previous Board member of a NASDAQ-listed biopharmaceutical company

Jean Franchi
Non-executive Director
- 20+ years of experience building finance & accounting systems and teams in life sciences
- Currently CFO of Replimune Group; served as SVP Corporate Finance at Genzyme, a biotech company with over $4B in revenue, and as CFO of Merrimack Pharmaceuticals, Dimension Therapeutics and Good Start Genetics

Zita Peach
Non-executive Director
- Over 30 years of experience in the pharmaceutical, biotechnology, medical device & healthcare sectors
- Currently serves on the board of ASX-listed Starpharma Holdings, Monash IVF Group and Pacific Smiles Group. Previously held executive roles at ASX-listed CSL Limited and Fresenius Kabi

Tom Dooley
Non-executive Director
- 30 years of experience in pharma and medical devices, including contact lenses and eye care
- Most recently served as President of Alcon Japan, where he oversaw 1,300 employees, and $1B in revenue from contact lens products, medical devices, and pharma
- Served as Alcon’s country manager in Australia and New Zealand

Andrew Silverberg
Non-executive Director
- 20 years of experience in global money management, capital markets, and investment banking
- Currently serves as Investment Manager at Thorney Investment Group, Pty.
- Previously served in senior roles at Talpion Fund Management, Mark Asset Management, and Fred Alger Management
What we do: Contact lenses

Visioneering produces innovative contact lenses that address two high-need and underserved populations worth up to $25bn combined:

$13-17bn global TAM

Near-sighted children, or paediatric myopia

- Affects up to one-third of children in US and 80-90% of children in many Asian nations, 2 billion people worldwide
- Correlates to elevated life-time risk for blindness and other debilitating ocular diseases
- Risk for ocular diseases correlates with level of near sightedness
- No widely adopted solutions are available
- US$2bn addressable market in US, ~$10bn China, plus other large OUS markets

$8bn global TAM

Adults over 45 losing up-close vision, or Presbyopia

- Affects nearly everyone over 45-50 in every part of the world
- Progressive disease; worsens with age
- Current contact lenses for presbyopia compromise either near or distance vision and are time-consuming for practitioners to optimize
- US$3bn addressable market in US, large OUS markets
Options to slow Myopia Progression are limited and have drawbacks

Glasses or simple contacts only correct the nearsighted vision, but do not slow the progression of myopia. Some believe that simple correction of vision may even accelerate the progression of nearsightedness.

Myopia progression is caused by the abnormal lengthening of the eye, and generally remains untreated owing to the limited treatment options available and lack of awareness.

**Atropine**
Drug formulated as eyedrops or ointment for the eye.

- Uncertain efficacy
- Significant side effects
- Rebound effect
- Temporary use only
- Difficult to obtain
- PDL: “Should not be supplied”

**Ortho-K**
Hard contact lenses worn at night to reshape the front surface of the eye.

- Expensive
- Requires daily lens sanitization
- Loss of vision correction through day
- Limited optical powers
- High practitioner time and training
- Off-label for myopia progression control

**Soft contact lenses**
High industry interest in soft contact lenses for myopia progression control.

- Several past and present attempts
- None have achieved widespread adoption
- Highly variable published data
Data support Visioneering’s NaturalVue MF ability to slow or stop myopia progression in children*

15 eye care professionals followed actual patients wearing VTI’s NaturalVue MF contact lenses

Length of follow up was up to 5 years in 305 eyes (153 children)

- 93% showed decrease in rate of myopia progression
- 65% showed decrease of 70% or greater
- 55% slowing of axial elongation

* Presented at the Global Myopia Symposium, October 2020
Contact lenses also have benefits for over-45 adults

**Superior clinical performance**
- The NaturalVue MF contact lens solves the near vision problem
- Simultaneously provides superior near, intermediate and distance vision.

![POMET Trial – near, intermediate & distance vision (n=59)](chart)

**Easier to fit**
- Currently marketed MF contact lenses require multiple visits (up to 6) to achieve a successful fit a majority of the time\(^1\)
- In Visioneering’s clinical trial, NaturalVue was successfully fit in an average of 1.1 visits vs 2.4 for a leading MF competitor\(^2\)

![Average fitting visits – NaturalVue MF vs Competitor MF](chart)

1. As reported by ECPs when fitting presbyopic patients
2. As reported by the manufacturer of the contact lens
Plans to expand on clinical data

- NaturalVue MF contact lenses have been studied in a real-world setting in 153 children for up to 5 years, and have been shown to slow or stop the progression of nearsightedness in children.
- Peer-reviewed evidence from real-world use in children has led to VTI’s NaturalVue MF contacts being prescribed to children around the world.
- The next phase of clinical data will be in prospectively designed clinical trials that are randomized and compared to a control product. The data from these additional studies will be used to support additional market penetration, to support approval in the US$10b market of China, and to open and accelerate strategic opportunities.
- Initiation of these trials is underway, with enrollment expected to begin 2Q2021.
- Trials will last approximately 3 years, though one-year data is expected 3Q2022.
- If 1-year data is positive, VTI expects the data to catalyse further market penetration and strategic development efforts.
- Such trials are capital efficient, requiring US$1.7-$3.4M, spread over 3.5 years.
VTI at forefront of rapidly expanding awareness of myopia

**Menicon**
Launched entire brand around myopia control called Menicon Bloom. Entered private label agreement with VTI for Europe.

**Global Myopia Awareness Coalition (GMAC)**
This is a coalition of the largest eye care companies to join forces in creating awareness in myopia.
VTI is a founding member and sits alongside the world’s largest eye care companies.

**Essilor**
World’s largest eye care company, formed task force for myopia control, Myopia In Action (M.I.A.)

**J&J Vision Care**
Initiated $25M research collaboration with Singapore for myopia control treatments (no products available or in publicly listed clinical trials).
Recently announced large clinical research project for drug-eluting contact lenses.

**Alcon**
IPO’d/spun out of Novartis and called out myopia control as an area of market expansion opportunity for the company (no products available or in publicly listed clinical trials).

**Bausch Health**
Recently began in-licensing of technologies for myopia control.

**Coopervision**
Coopervision has had a myopia control contact lens available outside the US for many years; not widely used. Recently entered the United States, but FDA requiring extensive clinical trial. Entered JV with Essilor for spectacles.

**World Council of Optometry**
The organization, which operates as an advisory board under the World Council of Optometry, has 11 corporations committed to this effort. These include Alcon, CooperVision, Essilor, Euclid Systems Corporation, Hoya, Johnson & Johnson, Menicon, Nevakar, Oculus, SightGlass Vision, and Visioneering Technologies.
Strategic Partnership Signed with Menicon Ltd

• Menicon Co., Ltd. is Japan's first and largest contact lens manufacturer founded by Mr Kyoichi Tanaka in 1951, and is now represented in over 80 countries with US$700M annualized revenue

• Menicon announced new myopia control brand in May 2019, Menicon Bloom


• Expands footprint of NaturalVue MF with large contact lens company

• Structure of non-exclusive cancellable deal allows VTI to maintain strategic flexibility
II. Investment Opportunity
### Worldwide Markets for pediatric myopia control

<table>
<thead>
<tr>
<th>Geography</th>
<th>Market Size (US$)</th>
<th>VTI Status/Partner</th>
<th>VTI Clearance</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States</td>
<td>$2 bn</td>
<td>Launched-Direct</td>
<td>Myopia/Presby</td>
</tr>
<tr>
<td>Australia/NZ</td>
<td>$0.3 bn</td>
<td>Launched-Corneal Lens Corporation</td>
<td>MPC/Myopia/Presby/Presby</td>
</tr>
<tr>
<td>Europe</td>
<td>$1 bn</td>
<td>Launched-Menicon, Positive Impact</td>
<td>MPC/Myopia/Presby/Presby</td>
</tr>
<tr>
<td>Canada</td>
<td>$0.4 bn</td>
<td>Launched-Direct</td>
<td>MPC/Myopia/Presby/Presby</td>
</tr>
<tr>
<td>Hong Kong</td>
<td>$0.1 bn</td>
<td>Launched-Oculus</td>
<td>MPC/Myopia/Presby/Presby</td>
</tr>
<tr>
<td>China</td>
<td>$7-10 bn</td>
<td>2024 Est</td>
<td>Expect MPC</td>
</tr>
<tr>
<td>Singapore/Korea</td>
<td>$0.7 bn</td>
<td>Singapore launched-Oculus</td>
<td>MPC/Myopia/Presby/Presby</td>
</tr>
<tr>
<td>Japan</td>
<td>$1.4 bn</td>
<td>2025 Est</td>
<td>MPC/Myopia/Presby</td>
</tr>
</tbody>
</table>

MPC = Myopia Progression Control
Presby = Presbyopia
Strong growth in revenue, 4yr CAGR of 60%

- **FY20 net revenue US$5.1m** (unaudited, fiscal=calendar year)
- **FY20 net cash used US$6.4m, 49% reduction YoY**
- **US$5.4m cash receipts from customers**
- **US$5.6m shipments to US ECPs**
- **Active accounts grew to 2,074**
- Accomplished with ~50% headcount reduction
- Gross margin of 43.6%, increased from 34.4% in 2019
- **Forecast US$7.0m revenue in FY21**
- **Strong start to 2021**, vis-a-vis peak virus in US and EU
  - At midpoint in 1QFY21, VTI has recorded US$847 in Shipments to US ECPs and US$800K in net revenue

Shipments to US ECPs represents gross value to VTI of shipments going from distributors’ inventories to US practitioners, and removes effect of inventory changes at distributor level

*Does not include Menicon stocking order of US$476K*
**Value Drivers in 2021 and Beyond**

Timings of milestones and achievements are approximate

<table>
<thead>
<tr>
<th>Q1 2021</th>
<th>Q2 2021</th>
<th>Q3 2021</th>
<th>Q4 2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expanded Menicon roll-out of <strong>Bloom Day</strong> throughout Europe, others accelerating in Singapore and HK, VTI in US/Canada</td>
<td>Projected 2021 sales of US$7m, +40% on FY20</td>
<td>Launch of <strong>NaturalVue MF Toric</strong></td>
<td>Initiate randomised trial in N. America for myopia progression control</td>
<td>Initiate randomised trial for approval in China for myopia progression control</td>
</tr>
</tbody>
</table>

**Continued discussions with potential strategic partners including but not limited to licensing, cross-selling, and mergers**

- Timings of milestones and achievements are approximate
III. Offer Summary
## Offer Summary

### Conditional Placement and Entitlement Offer with a free attaching option to raise up to A$23m ("Offer")

| Placement | Conditional Placement to institutions, sophisticated and professional investors to raise up to A$22m million via the issue of CDIs (Australia) and shares (US):  
|---|---  
|   | • Issue Price A$0.017 per share  
|   | • Subject to shareholder approval at a meeting of shareholders expected on or around 17 March 2021  

| Share Purchase Plan | Share Purchase Plan (SPP) to eligible CDI holders to raise up to A$1.0m  
|---|---  
|   | • Eligible CDI have the ability to apply for up to A$30,000  
|   | • Issue Price A$0.017 per share  

| Free attaching option | Participants in the Offer will receive 1 free listed option for every 2 CDIs subscribed for under the Offer. The options will be ASX listed (subject to ASX and shareholder approval) with a strike price of A$0.03, exercisable at any time prior to maturity in February 2024  

| Pricing | The Offer Price of A$0.017 represents an approximate:  
|---|---  
|   | 15% discount to the 15-day VWAP  
|   | 13.4% discount to the 5-day VWAP  

| Joint Lead Managers | Bell Potter Securities Limited and Aurenda Partners Pty Ltd  

# Use of Funds

<table>
<thead>
<tr>
<th>Activity</th>
<th>Amount (US$m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Data</td>
<td>$3.5</td>
</tr>
<tr>
<td>New Product Launches</td>
<td>$2.0</td>
</tr>
<tr>
<td>Sales and Marketing</td>
<td>$0.7</td>
</tr>
<tr>
<td>Working Capital (including inventory build)</td>
<td>$9.6</td>
</tr>
<tr>
<td>Capital Raising Costs</td>
<td>$1.2</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$17.0</strong></td>
</tr>
</tbody>
</table>
## Offer Timetable

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trading halt</td>
<td>Monday, 15 February 2021</td>
</tr>
<tr>
<td>Transaction announced &amp; Company resumes trading</td>
<td>Wednesday, 17 February 2021</td>
</tr>
<tr>
<td>Shareholder meeting to approve Placement</td>
<td>Wednesday, 17 March 2021</td>
</tr>
<tr>
<td>SPP opens</td>
<td>Thursday, 18 March 2021</td>
</tr>
<tr>
<td>Placement Settlement of new CDIs</td>
<td>Monday, 22 March 2021</td>
</tr>
<tr>
<td>Placement Allotment of new CDIs</td>
<td>Tuesday, 23 March 2021</td>
</tr>
<tr>
<td>SPP closes</td>
<td>Tuesday, 1 April 2021</td>
</tr>
</tbody>
</table>